The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term Clinical Effects of Epalrestat, an Aldose Reductase Inhibitor, on Diabetic Peripheral Neuropathy
Open accessAbstract
OBJECTIVE—We sought to evaluate the long-term efficacy and safety of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy. RESEARCH DESIGN AND METHODS—Subjects with diabetic neuropathy, median motor nerve conduction velocity (MNCV) ≥40 m/s, and HbA1c ≤9% were enrolled in this open-label, multicenter study and randomized to 150 mg/day epalrestat or a control group. After excluding the withdrawals, 289 (epalrestat group) and 305 (control group) patients were included in the analyses. The primary end point was change from baseline in median MNCV at 3 years. Secondary end points included assessment of other somatic nerve function parameters (minimum F-wave latency [MFWL] of the median motor nerve and vibration perception threshold [VPT]), cardiovascular autonomic nerve function, and subjective symptoms. RESULTS—Over the 3-year period, epalrestat prevented the deterioration of median MNCV, MFWL, and VPT seen in the control group. The between-group difference in change from baseline in median MNCV was 1.6 m/s (P < 0.001). Although a benefit with epalrestat was observed in cardiovascular autonomic nerve function variables, this did not reach statistical significance compared with the control group. Numbness of limbs, sensory abnormality, and cramping improved significantly with epalrestat versus the control group. The effects of epalrestat on median MNCV were most evident in subjects with better glycemic control and with no or mild microangiopathies. CONCLUSIONS—Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, particularly in subjects with good glycemic control and limited microangiopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Self-citationSima, A. A. F., Thomas, P. K., Ishii, D., & Vinik, A. (1997) · Diabetologia · doi:10.1007/bf03168192 · Cited by 822
Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy
Cameron, N. E., Eaton, S. E. M., Cotter, M. A., & Tesfaye, S. (2001) · Diabetologia · doi:10.1007/s001250100001 · Cited by 701
Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus
Partanen, J., Niskanen, L., Lehtinen, J., Mervaala, E., Siitonen, O., & Uusitupa, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199507133330203 · Cited by 656
Polyol pathway and diabetic peripheral neuropathy
Oates, P. J. (2002) · International Review of Neurobiology · doi:10.1016/s0074-7742(02)50082-9 · Cited by 322
Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy
Greene, D. A., Arezzo, J. C., Brown, M. B., & the Zenarestat Study Group (1999) · Neurology · doi:10.1212/wnl.53.3.580 · Cited by 278
Self-citationVinik, A. I., & Mehrabyan, A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.009 · Cited by 229
The Application of the Principle of Intention–to–Treat to the Analysis of Clinical Trials
Gillings, D., & Koch, G. (1991) · Drug Information Journal · doi:10.1177/009286159102500311 · Cited by 228
Hotta, N., Toyota, T., Matsuoka, K., Shigeta, Y., Kikkawa, R., Kaneko, T., Takahashi, A., Sugimura, K., Koike, Y., Ishii, J., et al. (2001) · Diabetes Care · doi:10.2337/diacare.24.10.1776 · Cited by 217
Self-citationAldose reductase inhibitors: therapeutic implications for diabetic complications
Oates, P. J., & Mylari, B. L. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.12.2095 · Cited by 197
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s94 · Cited by 176
Kohara, N., Kimura, J., Kaji, R., Goto, Y., Ishii, J., Takiguchi, M., & Nakai, M. (2000) · Diabetologia · doi:10.1007/s001250051469 · Cited by 147
Bril, V., Buchanan, R. A., & the Ranirestat Study Group* (2006) · Diabetes Care · doi:10.2337/diacare.29.01.06.dc05-1447 · Cited by 128
Self-citationHotta, N., Sakamoto, N., Shigeta, Y., Kikkawa, R., & Gotō, Y. (1996) · Journal of Diabetes and its Complications · doi:10.1016/1056-8727(96)00113-4 · Cited by 92
Self-citationBril, V., Buchanan, R. A., & the AS-3201 Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2369 · Cited by 87
Self-citationGoto, Y., Hotta, N., Shigeta, Y., et al. (1995) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(96)82642-4 · Cited by 85
Self-citationNakayama, M., Nakamura, J., Hamada, Y., Chaya, S., Mizubayashi, R., Yasuda, Y., Kamiya, H., Koh, N., & Hotta, N. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1093 · Cited by 47
Self-citationHotta, N. (1997) · PubMed · doi:10.18999/nagjms.60.3-4.89 · Cited by 45
Self-citationIkeda, T., Iwata, K., & Tanaka, Y. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00015-7 · Cited by 37
Treatments for diabetic neuropathy
Boulton, A. J. M. (2001) · Current Diabetes Reports · doi:10.1007/s11892-001-0024-8 · Cited by 16
Hotta, N., Yasuda, K., Sumita, Y., Sano, T., Kakuta, H., Nagashima, M., Hayashi, Y., Yamamoto, M., Wakao, T., Okuyama, M., et al. (2004) · Clinical Drug Investigation · doi:10.2165/00044011-200424110-00006 · Cited by 13
Self-citation
Cited by
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Diabetic neuropathy: Mechanisms to management
Edwards, J. L., Vincent, A. M., Cheng, H. T., & Feldman, E. L. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.05.005 · Cited by 790
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Metadata
- Authors
- Hotta, N., Akanuma, Y., Kawamori, R., Matsuoka, K., Oka, Y., Shichiri, M., Toyota, T., Nakashima, M., Yoshimura, I., Sakamoto, N., Shigeta, Y., & the ADCT Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-07-01
- Volume
- 29
- Issue
- 7
- Pages
- 1538-1544
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2154893083
- Cited by
- 366
- References
- 24
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.